Announcements
- Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
- Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
- Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
- Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review
- Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week
- Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
- Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
- Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
- Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | 3.76 |
Offer | 4.05 |
Previous close | 3.76 |
Average volume | -- |
---|---|
Shares outstanding | 8.73m |
Free float | 4.20m |
P/E (TTM) | -- |
Market cap | 20.48m USD |
EPS (TTM) | -1.94 USD |
Data delayed at least 15 minutes, as of Jan 10 2023 07:15 GMT.
More ▼